Moritz graduated in Pharmaceutical Sciences at the University of Freiburg in 2021 and conducted his Ph.D. studies in medicinal chemistry with Felix Hausch at the Technical University of Darmstadt. His Ph.D. focused on designing macrocyclic FKBP51 inhibitors with diverse linkers, where systematic derivatization improved their pharmacological profile and enabled analysis of linker effects on 3D structure. During his Ph.D. research, he spent three months as a visiting scientist at AbbVie, working on a project investigating macrocyclization as a strategy for optimizing ADME profiles. In October 2024, Moritz joined the Miller group to work on the development of PROTACs.